Further analyses also showed a similar association of SGLT2 inhibitors with HF hospitalization (eFigure 7 in Supplement 1) and CV death (eFigure 8 in Supplement 1), but not statistically significant on all-cause mortality (eFigure 9 in Supplement 1). This evidence concerns the gene SLC5A2 and hydrops fetalis.